ADAG

Adagene Inc.

2.53 USD
-0.37 (-12.76%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Adagene Inc. stock is down -9.32% since 30 days ago. The next earnings date is Jul 5, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 3 June’s closed higher than May.

About Adagene Inc.

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 mAb that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma.